A UK-based pharmaceutical SME is looking for novel small molecules with activity again Gram negative bacteria, especially resistant strains. The SME will further develop these novel compounds to improve their efficacy and safety profiles with a view to licensing the improved molecules to larger pharmaceutical companies to take onto the market. The SME seeks to partner with Universities, Research Institutes and SMEs in the form of a licensing agreement or technical cooperation agreement.
The emergence of antibiotic resistant strains of bacteria has made the development of new anti-bacterial compounds a matter of urgency. This is particularly the case for Gram negative bacterial species such as Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter cloacae.
A UK-based drug discovery and development company with subsidiary companies specialising in oncology, immunology and anti-infectives, is looking to partner with Universities, Research Institutions and other SMEs who may have novel small molecules with activity against Gram negative bacteria, particularly with activity against Multi-Drug Resistant strains. They are also interested in novel targets for Gram negative bacteria with chemical starting matter. The SME is looking for very early stage small molecules that it can further develop the compounds by improving activity, drug-like properties and safety profiles. The company has expertise in medicinal chemistry, computational chemistry, microbiology, drug metabolism and pharmacokinetics, analytical and business development; and are able to add significant value to a compound /program with the capability of taking the asset through preclinical development as well as Phase 1 clinical trial stage with the aim of licensing on to a larger pharmaceutical company for further development and market registration.
It is envisaged that the partnership with the University, Research Institution or SME would be in the form of a licensing agreement, although technical cooperation agreements will also be considered where appropriate and the company is open to other forms of collaboration.
- Type of partner sought: The UK-based SME is looking for novel small molecules with activity against Gram negative bacteria, especially multi-drug resistant strains. They are especially looking for molecules at a very early stage of development. As well as access to the molecules and their chemical structure data the SME would also require the data generated to date on activity and safety profiles.
The SME is looking for novel small molecule compounds against a validated target. They will also consider novel targets but will require additional chemistry data in order to pursue these compounds. The SME will not consider biological molecules such as peptides nor compounds that are not novel.
- Specific area of activity of the partner: The UK-based SME is looking to partner with Universities, Research Institutions and other SMEs that have identified novel small molecules that have activity against Gram negative bacteria such as Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter cloacae and in particular multi-drug resistant strains.
The UK-based SME will develop these early-stage molecules through an optimisation process improving their activity and safety profiles. The SME will take these molecules up to Phase 1 clinical trials with the aim of then licensing them on to larger pharmaceutical companies for later stage clinical trials.
It is anticipated that these partnerships will take the form of a licensing agreement whereby the SME will in-license the novel small molecules from the partner. Alternatively a technical cooperation agreement will also be considered where appropriate.
01/05/2018 - Selling Online Internationally - Shetland
02/05/2018 - Selling Online Internationally - Orkney